Ivermectin, two other drugs tested in the MUSC COVID-19 clinical trial

CHARLESTON, SC (WCSC) – Ivermectin, a drug used to treat parasitic infections, has recently received a lot of attention over whether it should be used to treat COVID-19. Now, this drug and two others are being tested in a COVID-19 clinical trial in which MUSC is participating.

According to MUSC, there are limited options for COVID-19 treatments that are approved by the FDA and are intended for patients who are not sick enough to be hospitalized. Doctors with MUSC said they hoped this trial would help answer some questions about various treatments and dispel any incorrect information that was swirling around.

“We’ve seen a lot of misinformation out there, and unfortunately some patients have been given drugs not approved by the FDA outside of a clinical trial,” Rami Zebian, MD said in a statement. “It is not a safe practice, and we have seen many reports of toxicity – and we have many unanswered questions.”

In addition to ivermectin, fluticasone, a corticosteroid used for asthma and other conditions, and fluvoxamine, an antidepressant, are also included in the study.

MUSC officials said it was a safe way to see if these drugs are actually effective in reducing symptoms of the virus.

According to MUSC, this study is completely remote, so you don’t have to live near a MUSC campus to participate. You can also choose the medicine that is right for you and you will be given either a placebo or the medicine.

MUSC officials have said that if you are accepted into the trial, you will take the drug as directed, complete daily surveys, and respond to appeal questionnaires. After 90 days, each attendee will receive a $ 100 Amazon gift card.

To be eligible to participate in the study, you must be at least 30 years old, have a positive covid test within the past 10 days, and live at least two COVID symptoms.

Copyright 2021 WCSC. All rights reserved.